Tivic Health Launches B2B Portal, Accelerates Healthcare Commercial Sales Expansion
08 Maio 2023 - 10:15AM
Business Wire
Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health
tech company that develops and commercializes bioelectronic
medicine, announced today that it has launched a B2B portal to
support its increasing demand for commercial ordering of its doctor
recommended and FDA-approved bioelectronic sinus device, ClearUP.
This portal is available to pharmacy groups and healthcare
providers, in addition to wholesalers and distributors.
ClearUP is a drug-free therapy that provides relief from allergy
sinus pain, sinus headaches, sinus pressure, and congestion.
“I recommend ClearUP for treating the symptoms of allergic
inflammation and having the ClearUP product available in medical
practices makes it easy for patients to start using it as part of
their daily regimen,” said Dr. Alan Goldsobel, Adjunct Clinical
Professor at Stanford University School of Medicine and past
President of the California Society of Allergy, Asthma, &
Immunology. “My patients are looking for effective solutions beyond
the use of medications.”
Tivic’s B2B portal provides a streamlined ordering and
fulfillment process for professional customers and reduces the
company’s logistical complexity and costs for supporting these
commercial partnerships. The launch of this new platform is a clear
step in the company’s commitment to provide customers with a
seamless experience while supporting its growth engine.
“The B2B portal will further enable our commercial and
operational reach as we accelerate growth,” said Jennifer Ernst,
CEO of Tivic. “This is one of many steps towards increasing access
of bioelectronic medicine for all patients that can benefit from
drug-free clinically effective therapeutic solutions.”
About Tivic
Tivic is a commercial health tech company advancing the field of
bioelectronic medicine. Tivic’s patented technology platform
leverages stimulation on the trigeminal, sympathetic, and vagus
nerve structures. Tivic’s non-invasive and targeted approach to the
treatment of inflammatory chronic health conditions gives consumers
and providers drug-free therapeutic solutions with high safety
profiles, low risk, and broad applications. Tivic’s first
commercial product ClearUP is an FDA approved, award-winning,
handheld bioelectronic sinus device. ClearUP is clinically proven,
doctor-recommended, and is available through online retailers and
commercial distributors. For more information visit
http://tivichealth.com @TivicHealth
Forward-Looking Statements
This press release may contain “forward-looking statements” that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will” “would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on Tivic Health
Systems, Inc.’s current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to
predict. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements. For a discussion of
certain risks and uncertainties, and other important factors, any
of which could cause Tivic’s actual results to differ from those
contained in the forward-looking statements, see Tivic’s filings
with the SEC, including, its Annual Report on Form 10-K for the
year ended December 31, 2022, filed with the SEC on March 31, 2023,
under the heading “Risk Factors”; as well as the company’s
subsequent filings with the SEC. Forward-looking statements
contained in this press release are made as of this date, and Tivic
Health Systems, Inc. undertakes no duty to update such information
except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230508005241/en/
Media Contact: Kayleigh Westerfield 949-632-3439
Kayleigh.Westerfield@tivichealth.com
Investor Contact: Hanover International, Inc.
ir@tivichealth.com
Tivic Health Systems (NASDAQ:TIVC)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tivic Health Systems (NASDAQ:TIVC)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024